This compound is an active pharmaceutical ingredient impurity associated with alogliptin. It is characterized by a pyrimidinedione core with an aminopiperidine substituent and a benzonitrile group.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 865759-26-8
Cupric citrate
active pharmaceutical ingredient
Ceftaroline fosamil acetate hydrate
active pharmaceutical ingredient prodrug
(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile
active pharmaceutical intermediate
7-Ethyl-10-hydroxycamptothecin
active pharmaceutical ingredient
(S)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile
oral anti-diabetic DPP-4 inhibitor
2-[[6-[(3R)-3-aminopiperidin-1-yl]-2,4-dioxo-3-(trideuteriomethyl)pyrimidin-1-yl]methyl]benzonitrile
Pharmaceutical intermediate for alogliptin synthesis
Alogliptin (13CD3)
stable isotope labeled active pharmaceutical ingredient
(S)-Alogliptin Benzoate Salt
active pharmaceutical ingredient
2-[[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
ZSBOMTDTBDDKMP-UHFFFAOYSA-N
CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
—